Skip to content
Clinical ResearchResearch compound

MK‑677 (Ibutamoren)

Experimental growth-hormone-boosting compound taken by mouth (not a SARM); it worsened blood sugar in a human trial.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

MK-677 (Ibutamoren) vial

DETAILED OVERVIEW

What is MK-677 (Ibutamoren)?

MK-677 (ibutamoren) is an experimental compound that, taken by mouth, increases the release of growth hormone and thereby the level of IGF-1 (a substance that carries out the effects of growth hormone). It has never been approved as a medicine, and its clinical development was halted. It is not a SARM: it does not act on the receptor for male hormones and does not suppress the body's own testosterone production.

In a two-year placebo-controlled trial in older adults, growth hormone and IGF-1 returned to the range typical of young adults, and fat-free body mass rose by about 1.1 kg. Meanwhile carbohydrate metabolism got worse: fasting blood sugar and insulin resistance increased, and this did not settle during the trial. It causes a strong increase in appetite, and water retention and numb hands can also occur. It is contraindicated in diabetes, prediabetes and heart failure, and it must not be used in pregnancy. It is banned in competitive sport all year round.

Mechanism

Ghrelin (hunger hormone) receptor stimulator; more growth hormone, IGF-1

Body composition (Nass 2008)

In older adults, fat-free body mass rose by about 1.1 kg

Critical adverse effect

Worsening insulin sensitivity and rising fasting glucose that did not resolve during the trial.

Half-life

~4-6 h, but the IGF-1 elevation is sustained, so once-daily dosing suffices.

Legal status

Never approved. WADA-banned (S2, GH secretagogues).

Data console

Lab data

Androgenic:AnabolicNot applicable: MK-677 is not an androgen and does not bind the androgen receptor.
AR bindingNon-peptide GHSR-1a agonist. It has no androgen receptor…
Active half-life~4-6 h
Detection windowWADA-accredited laboratories detect it in urine by LC-MS/MS. Banned year-round in competitive sport (S2).
AromatizationNO. MK-677 is not a steroid, is not a substrate of aromatase (CYP19) and does not directly raise estradiol.
HepatotoxicityLOW. It is not 17-alpha-alkylated, so classic oral-steroid hepatotoxicity does not apply. In the two-year Nass 2008 trial the limiting safety factor was carbohydrate metabolism, not the liver. Monitoring should therefore focus on fasting glucose and HbA1c rather than ALT/AST.

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Marked appetite increase: the direct, expected consequence of ghrelin receptor agonism. For many this is the strongest noticeable effect, and a serious drawback during a cutting phase.
  • Worsening insulin sensitivity and rising fasting glucose: in the two-year Nass 2008 trial this was the most significant metabolic adverse effect, and it did not resolve during treatment.
  • Water retention and peripheral edema: a classic accompaniment of GH axis activation, typically most pronounced in the first weeks.
  • Carpal-tunnel-like complaints: numbness and paraesthesia in the hand from soft-tissue swelling, usually easing on dose reduction.
  • Lethargy and daytime drowsiness, especially in the introductory phase; many therefore switch to evening dosing.
  • Mild prolactin and cortisol elevation: usually clinically insignificant, but worth measuring if symptoms appear.

Contraindications · 5

  • Diabetes, prediabetes or insulin resistance: MK-677 documentedly worsens glucose metabolism, an absolute contraindication.
  • Active or treated malignancy: elevated IGF-1 carries a theoretical proliferative risk, avoid without oncology consultation.
  • Heart failure or untreated hypertension: fluid retention places further load on the circulation.
  • Pregnancy and breastfeeding: no safety data, use is prohibited.
  • Competitive sport under testing: WADA bans GH secretagogues (S2), with the same sanction as growth hormone itself.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about MK‑677 (Ibutamoren)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.